Jocelyn Trottier, Mélanie Verreault, Susan Grepper, Didier Monté, Julie Bélanger, Jenny Kaeding, Patrick Caron, Ted T. Inaba, Olivier Barbier – 20 October 2006 – Chenodeoxycholic acid (CDCA) is a liver‐formed detergent and plays an important role in the control of cholesterol homeostasis. During cholestasis, toxic bile acids (BA) accumulate in hepatocytes causing damage and consequent impairment of their function. Glucuronidation, a conjugation reaction catalyzed by UDP‐glucuronosyltransferase (UGT) enzymes, is considered an important metabolic pathway for hepatic BA.

Timothy McCashland – 18 October 2006

Swan N. Thung – 18 October 2006 – Key Concepts: 1The histopathologic presentation of hepatitis B (HB) infection in liver allografts is generally similar to that seen in the nonallografts.2An atypical pattern of recurrent HB, i.e., fibrosing cholestatic hepatitis (FCH) occurs in a small number of patients.

Nathan M. Bass, Bernard C. Portmann, Michael R. Lucey – 18 October 2006

Michael F. Sorrell – 18 October 2006

Laura E. Moreno Luna, Gregory J. Gores – 18 October 2006

Robert G.

Debra L. Sudan – 18 October 2006

Lydia M. Petrovic – 18 October 2006 – Key Concepts: 1Early recurrence of hepatitis C is universal.2Typical histopathologic features of hepatitis C virus (HCV) and acute allograft rejection (AAR) exist.3Early recurrent HCV may be differentiated from AAR.4Liver biopsy plays a role in diagnosing HCV and AAR.5Risk factors for recurrent HCV should be known.6The natural history of recurrent HCV should be known.7The future role of ancillary studies beyond liver biopsy is assessed. Liver Transpl 12:S32–S37, 2006. © 2006 AASLD.

Anthony Jake Demetris – 18 October 2006 – Key Concepts: 1Recurrent primary sclerosing cholangitis (PSC) is extremely difficult, if not impossible, to distinguish from other causes of biliary strictures or sclerosing cholangitis in allografts using needle biopsy evaluation alone.